MOBI
MOBI
Mobia Medical, Inc. Common StockIncome Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $12.07M | $26.88M | $-17.74M | -146.93% | $-0.54 | $-17.33M |
What's going well?
Gross margins are strong at 82%, meaning the core product or service is valuable. No one-time charges or accounting tricks – results are straightforward.
What's concerning?
Operating expenses are more than double revenue, leading to big losses. The company is losing $1.47 for every $1 it brings in, with no sign of improvement or growth data.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $55.73M | $73.6M | $241.34M | $-167.75M |
What's financially strong about this company?
The company has a strong cash position, with $55.7M in cash and a very high current ratio. Most assets are high-quality and liquid, with no risky goodwill or intangibles.
What are the financial risks or weaknesses?
Shareholder equity is deeply negative, meaning the company owes much more than it owns. Debt is high compared to assets, and there is a long history of losses.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $-17.74M | $-17.73M | $-42K | $39.91M | $22.14M | $-17.77M |
What's strong about this company's cash flow?
The company still has $55.7 million in cash, giving it some breathing room for now. Capital spending is very low, so cash needs aren't rising due to investments.
What are the cash flow concerns?
The business is burning real cash every quarter and depends on outside funding to survive. Working capital is also draining cash, and there are no returns for shareholders.
5-Year Trend Analysis
A comprehensive look at Mobia Medical, Inc. Common Stock's financial evolution and strategic trajectory over the past five years.
Key strengths include a highly differentiated, FDA-approved device addressing a large unmet clinical need; strong clinical evidence that shows superior outcomes versus standard therapy; and very high gross margins that suggest attractive unit economics if scale is achieved. Short-term liquidity is solid, with cash exceeding near-term obligations, and the company has shown it can access equity financing. A focused R&D program and first-mover status in paired VNS for stroke further reinforce its strategic position.
Major risks stem from the financial profile: large and persistent operating losses, heavy cash burn, and a balance sheet with negative equity and substantial non-current liabilities. The business is dependent on continued external funding until it can materially improve operating cash flow. Commercial execution risk is also high—adoption by physicians, reimbursement coverage, and patient uptake all need to ramp meaningfully. Competition from alternative neurorehabilitation technologies, concentration on a single flagship product, and the potential for shareholder dilution add to the risk profile.
The outlook is highly execution-dependent. If Mobia can translate its clinical and regulatory lead into broad market adoption, grow revenue significantly, and bring operating costs under better control, the strong gross margins and large addressable market could materially improve its financial trajectory over time. Conversely, if adoption is slower than expected or capital markets become less supportive, the combination of ongoing cash burn and a stressed capital structure could become increasingly challenging. Overall, the company offers notable technological promise but carries elevated financial and operational uncertainty typical of early-stage, high-innovation medtech firms.
About Mobia Medical, Inc. Common Stock
https://www.mobia.comMobia Medical, Inc. functions as a commercial-level medical device enterprise, concentrating on developing therapeutic solutions for individuals recovering from strokes who experience motor impairments.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $12.07M | $26.88M | $-17.74M | -146.93% | $-0.54 | $-17.33M |
What's going well?
Gross margins are strong at 82%, meaning the core product or service is valuable. No one-time charges or accounting tricks – results are straightforward.
What's concerning?
Operating expenses are more than double revenue, leading to big losses. The company is losing $1.47 for every $1 it brings in, with no sign of improvement or growth data.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $55.73M | $73.6M | $241.34M | $-167.75M |
What's financially strong about this company?
The company has a strong cash position, with $55.7M in cash and a very high current ratio. Most assets are high-quality and liquid, with no risky goodwill or intangibles.
What are the financial risks or weaknesses?
Shareholder equity is deeply negative, meaning the company owes much more than it owns. Debt is high compared to assets, and there is a long history of losses.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $-17.74M | $-17.73M | $-42K | $39.91M | $22.14M | $-17.77M |
What's strong about this company's cash flow?
The company still has $55.7 million in cash, giving it some breathing room for now. Capital spending is very low, so cash needs aren't rising due to investments.
What are the cash flow concerns?
The business is burning real cash every quarter and depends on outside funding to survive. Working capital is also draining cash, and there are no returns for shareholders.
5-Year Trend Analysis
A comprehensive look at Mobia Medical, Inc. Common Stock's financial evolution and strategic trajectory over the past five years.
Key strengths include a highly differentiated, FDA-approved device addressing a large unmet clinical need; strong clinical evidence that shows superior outcomes versus standard therapy; and very high gross margins that suggest attractive unit economics if scale is achieved. Short-term liquidity is solid, with cash exceeding near-term obligations, and the company has shown it can access equity financing. A focused R&D program and first-mover status in paired VNS for stroke further reinforce its strategic position.
Major risks stem from the financial profile: large and persistent operating losses, heavy cash burn, and a balance sheet with negative equity and substantial non-current liabilities. The business is dependent on continued external funding until it can materially improve operating cash flow. Commercial execution risk is also high—adoption by physicians, reimbursement coverage, and patient uptake all need to ramp meaningfully. Competition from alternative neurorehabilitation technologies, concentration on a single flagship product, and the potential for shareholder dilution add to the risk profile.
The outlook is highly execution-dependent. If Mobia can translate its clinical and regulatory lead into broad market adoption, grow revenue significantly, and bring operating costs under better control, the strong gross margins and large addressable market could materially improve its financial trajectory over time. Conversely, if adoption is slower than expected or capital markets become less supportive, the combination of ongoing cash burn and a stressed capital structure could become increasingly challenging. Overall, the company offers notable technological promise but carries elevated financial and operational uncertainty typical of early-stage, high-innovation medtech firms.
CEO
Richard Foust
Compensation Summary
(Year )
Upcoming Earnings
ETFs Holding This Stock
Summary
Showing Top 2 of 16
Ratings Snapshot
Rating : C-